Evidence map›Paper›PMID 34585294›Full record

ArticleWorld journal of urology2022

Occult lymph node metastases in patients without residual muscle-invasive bladder cancer at radical cystectomy with or without neoadjuvant chemotherapy: a nationwide study of 5417 patients.

L M C van Hoogstraten, E J van Gennep, L A L M Kiemeney, J A Witjes, C S Voskuilen, M Deelen, L S Mertens, R P Meijer, J L Boormans, D G J Robbrecht and 7 more

Abstract read
In one paragraph

Article in World journal of urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Predictive Value of Preoperative [International journal of general medicine · 2025
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

L M C van HoogstratenDepartment of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands. l.vanhoogstraten@iknl.nl.ORCID http://orcid.org/0000-0002-0987-1342
E J van Gennep *Department of Urology, Leiden University Medical Center, Leiden, The Netherlands.
L A L M KiemeneyDepartment of Urology, Radboud University Medical Center, Nijmegen, The Netherlands.
J A WitjesDepartment of Urology, Radboud University Medical Center, Nijmegen, The Netherlands.
C S VoskuilenDepartment of Urology, Netherlands Cancer Institute-Antoni Van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
M DeelenDepartment of Urology, Maastricht University Medical Center+, Maastricht, The Netherlands.
L S MertensDepartment of Urology, Netherlands Cancer Institute-Antoni Van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
R P MeijerDepartment of Oncological Urology, University Medical Center Utrecht, Utrecht, The Netherlands.
J L BoormansDepartment of Urology, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands.
D G J RobbrechtDepartment of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands.
L V BeerepootDepartment of Medical Oncology, Elisabeth-TweeSteden Hospital, Tilburg, The Netherlands.
R H A VerhoevenDepartment of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands.
T M RippingDepartment of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands.
BlaZIB Study Group
B W G van RhijnDepartment of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni Van Leeuwenhoek, Amsterdam, The Netherlands.
K K H Aben *Department of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands.
T J N Hermans *Department of Urology, Catharina Hospital Eindhoven, Eindhoven, The Netherlands.

Funding

kwf kankerbestrijding IKNL 2015-7914
6 · The paper itself

Abstract

purposeLittle is known about the prevalence of occult lymph node metastases (LNM) in muscle-invasive bladder cancer (MIBC) patients with pathological downstaging of the primary tumor. We aimed to estimate the prevalence of occult LNM in patients without residual MIBC at radical cystectomy (RC) with or without neoadjuvant chemotherapy (NAC) or neoadjuvant radiotherapy (NAR), and to assess overall survival (OS).

methodsPatients with cT2-T4aN0M0 urothelial MIBC who underwent RC plus pelvic lymph node dissection (PLND) with curative intent between January 1995-December 2013 (retrospective Netherlands Cancer Registry (NCR) cohort) and November 2017-October 2019 (prospective NCR-BlaZIB cohort (acronym in Dutch: BlaaskankerZorg In Beeld; in English: Insight into bladder cancer care)) were identified from the nationwide NCR. The prevalence of occult LNM was calculated and OS of patients with <(y)pT2N0 vs. <(y)pT2N+ disease was estimated by the Kaplan-Meier method.

resultsIn total, 4657 patients from the NCR cohort and 760 patients from the NCR-BlaZIB cohort were included. Of 1374 patients downstaged to  <(y)pT2, 4.3% (N = 59) had occult LNM 4.1% (N = 49) of patients with cT2-disease and 5.6% (N = 10) with cT3-4a-disease. This was 4.0% (N = 44) in patients without NAC or NAR, 4.5% (N = 10) in patients with NAC, and 13.5% (N = 5) in patients with NAR but number of patients treated with NAR and downstaged disease was small. The prevalence of  <(y)pT2N+ disease was 4.2% (N = 48) in the NCR cohort and 4.6% (N = 11) in the NCR-BlaZIB cohort. For patients with  <(y)pT2N+ and  <(y)pT2N0, median OS was 3.5 years (95% CI 2.5-8.9) versus 12.9 years (95% CI 11.7-14.0), respectively.

conclusionOccult LNM were found in 4.3% of patients with cT2-4aN0M0 MIBC with (near-) complete downstaging of the primary tumor following RC plus PLND. This was regardless of NAC or clinical T-stage. Patients with occult LNM showed considerable worse survival. These results can help in counseling patients for bladder-sparing treatments.

Indexed as

CystectomyAgedCarcinoma, Transitional CellHumansLymphatic MetastasisNeoadjuvant TherapyNeoplasm InvasivenessNeoplasm, ResidualNetherlandsProspective StudiesRetrospective StudiesUrinary Bladder NeoplasmsBladder cancerDownstagingLymph node metastasesNeoadjuvant chemotherapyRadical cystectomy

Identifiers

PMID34585294
PMCPMC8813846

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.